PT Dexa Medica

A review.Despite its potential benefits, lutein availability can be limited due to inadequate dietary intake of fruits, vegetables, and seaweed.Addnl., lutein faces challenges related to gastrointestinal absorption due to its physicochem. characteristics.To tackle these issues, fortifying staple foods with lutein is proposed, but its low solubility and susceptibility to oxidative degradation present hurdles.Nanoencapsulation technol. emerges as a promising solution for improving lutein stability during food processing, storage, and absorption.However, lutein's stability remains a challenge, with susceptibility to degradation by temperature, UV-light, and oxygen exposure.Food processing involving high temperatures can cause degradation, while specific UV-wavelengths lead to cleavage of lutein mols.This critical viewpoint carries substantial scientific significance by urging researchers globally to prioritize clin. investigations and the advancement of plant-based lutein nanoencapsulation in basic dietary items.Clin. studies focusing on lutein-plant-based nanoencapsulation approaches are essential to improve its stability and bioaccessibility, ultimately contributing to better vision health.

Background. There are still some unmet needs for stroke management and safety. DLBS1033 is a protein fraction extracted from the earthworm Lumbricus rubellus that has shown fibrinolytic and fibrinogenolytic activities, reduces blood viscosity, and inhibits platelet aggregation that it can be considered an add-on therapy and potential medical breakthrough in acute ischemic stroke management. Objective. This study is aimed at measuring the benefit of DLBS1033 in acute ischemic stroke management. Methods. This was a randomized, open-label trial at a referral stroke center from November 2019 to December 2020. Subjects who met the inclusion criteria were randomly divided into a control group and an experimental group. The control group received standard therapy consisting of aspirin 100 mg once daily, atorvastatin 20 mg once daily, and vitamin B12 100 mg three times daily. The experimental group received standard therapy and DLBS1033 three times daily. The functional outcomes were measured using the National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS) at baseline, hospital discharge, and day 30. Results. Collected data from 180 subjects was analyzed. The NIHSS scores’ improvements were significantly greater in the experimental group compared to the control group at both hospital discharge (−5.57±2.16vs.−3.64±2.65;p<0.001) and day 30 (−6.62±2.64vs.−5.14±2.41;p=0.001). Compared with the control group, the improvements in the BI scores were significantly better in the experimental group, at both hospital discharge (10.69±5.36vs.6.64±5.04;p<0.001) and day 30 (10.9±8.19vs.8.56±7.45;p=0.003). The distribution of mRS scores was improved in both groups during 30 days of follow-up and was more favorable in the experimental group. In both groups, a favorable outcome (mRS<2) was achieved better at day 30 (86.7% vs. 80%;p=0.302) than at baseline (0% vs. 6.7%;p=0.028) and at hospital discharge (58.9% vs. 43.3%;p=0.085). There was no clinically significant adverse event related to the study product. Conclusions. DLBS1033 in addition to the standard care was more effective in improving functional status compared to standard care alone in acute ischemic stroke patients with a similar safety profile.

The current study aimed to evaluate whether a generic product of etoricoxib 120 mg film-coated tablet (the test drug) was bioequivalent to the reference product (Arcoxia® film-coated tablet 120 mg).

This was a randomized, open-label, two-sequence, crossover study under fasting condition, with a 14-day washout period, involving 26 healthy adult male and female subjects. Blood samples were taken and analyzed for plasma concentrations of etoricoxib (Chemical Abstracts Service [CAS] 202409-33-4) using a high-pressure liquid chromatography-ultraviolet detector (HPLC-UV) system capable of measuring etoricoxib concentrations ranging from 5.00 to 5002.90 ng/mL, with the lowest limit of quantitation of 5.00 ng/mL. A noncompartmental method was used to determine the pharmacokinetic parameters of a single-dose administration of the drug, including the area under plasma concentration-time curve from time zero to the time of last observed concentration (AUC_0-t ), the area under plasma concentration-time curve from time zero to infinity (AUC_0-∞), the maximum plasma concentration (C_max), the time to reach the maximum plasma concentration (t_max), and the terminal half-life (t_½).

After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC_0-72h and C_max of the test drug were 45913.42 (13142.19) ng·h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng·h/mL and 2915.13 (772.81) ng/mL, respectively. The geometric mean ratios (90% CIs) of the test drug/reference drug were 103.40% (98.70%-108.32%) for AUC_0-72h and 109.26% (100.18%-119.18%) for C_max. No clinically significant differences in t_max and t_½values were found between the test drug and the reference drug. No adverse events were experienced by the subjects during this study.

The present study demonstrated that the evaluated generic etoricoxib 120 mg film-coated tablets were bioequivalent to the reference drug.